EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches

Mili Prajapati, Vaishnavi Singh, Akash Mishra, Debnarayan Khatua, Minakshi Rana, Anupam Jyoti

Frontiers in Pharmacology · 17.06.2026 · 17

DOI: 10.3389/fphar.2026.1810887 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.06.2026. Verfasst von Mili Prajapati und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Parul Institute of Applied Science, Faculty of Applied Sciences, Parul University, Vadodara, India. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sepsis is a life-threatening condition characterized by simultaneous hyperinflammation and immunosuppression, which leads to organ dysfunction and mortality. It is a global health concern, which is estimated to be approximately 166 million cases and 21.4 million global deaths in 2021.

Aim

This review aimed to analyze sepsis epidemiology, pathophysiology, current therapeutic approaches and challenges, and assess the transformational role of modern therapeutic approaches, including precision medicine, and Artificial Intelligence (AI)/Machine Learning (ML) in sepsis. Methodology A literature search was carried out across multiple databases, including PubMed, Web of Science, and Scopus. The search was focused on hyperinflammation, immunosuppression in sepsis, current therapy, and future advances.

Result

The review integrated the search data from original articles, review papers, and clinical trials. After careful analysis, we observed that the efficacy of current therapy is limited due to the heterogeneity of sepsis patients, the lack of patient selection based on immune status, timing, and validated biomarkers. Precision methods based on classifying patient genotypes and multi-omics-based biomarkers suggest a potential approach to risk stratification and therapeutic guidance. Concurrently, AI/ML models exhibit improved predictive accuracy and early clinical diagnosis, facilitating early identification and risk stratification.

Conclusion

The integration of AI/ML and precision medicine into sepsis care has the potential to reduce mortality in clinically significant endotypes and allow focused immunomodulatory treatments fulfilling Sustainable Development Goal 3.

Schlagwörter

Stichwörter der Autor:innen

AI/MLheterogeneityhyperinflammationimmunosuppressionprecision medicinesepsis

Autor:innen und Institutionen

  • Department of Life Science, Parul Institute of Applied Science, Faculty of Applied Sciences, Parul University, Vadodara, India.
  • Department of Applied Science and Humanities, Parul Institute of Technology, Parul University, Vadodara, India.
  • Autoimmunity and Inflammation Program, Hospital for Special Surgery at Weill Cornell Medicine, New York, NY, United States.

Zitieren

APA

Prajapati, M., Singh, V., Mishra, A., Khatua, D., Rana, M., & Jyoti, A. (2026). Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1810887

Vancouver

Prajapati M, Singh V, Mishra A, Khatua D, Rana M, Jyoti A. Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1810887

BibTeX
@article{Prajapati2026,
  author = {Prajapati, Mili and Singh, Vaishnavi and Mishra, Akash and Khatua, Debnarayan and Rana, Minakshi and Jyoti, Anupam},
  title = {Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1810887}
}
Kostenlos starten →